VIDEO: Romidepsin linked with reduced size, viability of osteosarcoma sarcospheres
Click Here to Manage Email Alerts
TAMPA, Fla. — In a video at the Orthopaedic Research Society Annual Meeting, Emily E. Seiden, BS, discusses romidepsin, which showed promise as a therapeutic to target micrometastases progression in osteosarcoma.
Seiden said, “Osteosarcoma is the most malignant bone tumor in children and in adolescents and also in dogs. So, the lethality of this disease is due to lung metastases.” After Seiden and her colleagues screened potential drugs on sarcospheres, romidepsin, which is a histone deacetylase (HDAC) inhibitor, “was found to be the top hit of the entire screen.”
It was also the safest drug, even after researchers compared its effect to that of newer HDAC inhibitor drugs, and was synergistic with the standard of care MAP chemotherapy combination of methotrexate, doxorubicin and cisplatin, she said.
Results showed romidepsin reduced the viability and size of osteosarcoma sarcospheres, and its results with patient-derived sarcospheres from a canine patient showed it also reduced the viability of those sarcospheres, Seiden said.
Collapse
Seiden EE, et al. Paper 150. Presented at: Orthopaedic Research Society Annual Meeting. Feb. 4-8, 2022; Tampa, Fla.
Read more about
Click Here to Manage Email Alerts